Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

Chiara Tommasi, Rita Bellagamba, Massimo Tempestilli, Antonio D'Avolio, Anna L. Gallo, Jelena Ivanovic, Emanuele Nicastri, Leopoldo P. Pucillo, Pasquale Narciso

Research output: Contribution to journalArticlepeer-review

Abstract

The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone/proguanil and these anti-retroviral drugs are investigated. Pharmacokinetic analyses documented a marked increase in etravirine and saquinavir plasma concentrations (+55% and +274%, respectively), but not in raltegravir and maraviroc plasma concentrations. The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450.

Original languageEnglish
Article number141
JournalMalaria Journal
Volume10
DOIs
Publication statusPublished - 2011

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis'. Together they form a unique fingerprint.

Cite this